No Data
No Data
Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Looks Interesting, And It's About To Pay A Dividend
Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) stock is about to trade ex-dividend in four days. Typically, the ex-dividend date is one business day before the record date which is the date on
Ruipu Biotech (300119.SZ) plans to pay 4 yuan for 10 shares to be deducted from interest on May 15
Ruipu Biotech (300119.SZ) announced that the company's 2023 equity distribution plan: every 10 shares to all shareholders...
Ruipu Biology (300119.SZ): The main business areas are R&D, production and sales of veterinary biological products, veterinary pharmaceutical preparations (chemicals, Chinese veterinary drugs, disinfectants, etc.), veterinary raw materials, and veterinary
Gelonghui, May 7 | Ruipu Biotech (300119.SZ) said on the investor interactive platform that Ruipu Biotech is a high-tech enterprise serving the animal health industry. Its main business areas are R&D, production, sales of veterinary biological products, veterinary pharmaceutical preparations (chemicals, Chinese veterinary drugs, disinfectants, etc.), veterinary APIs, and the provision of overall animal disease prevention and control solutions. It is one of the largest and most comprehensive veterinary drug companies in China. It is also a major national animal disease prevention and control vaccine manufacturer. After rapid development, Chinese animal insurance enterprises have basically achieved success in the field of economic animals
Ruipu Biology (300119.SZ): It has a synthetic biotechnology platform with many leading technologies such as gene editing, gene synthesis, cell modification, and multiomics
Gelonghui, May 7 | Ruipu Biology (300119.SZ) said on the investor interactive platform that the company has a synthetic biotechnology platform, which has many leading technologies such as gene editing, gene synthesis, cell modification, protein mining and modification, high-throughput screening, high-throughput analysis, and multiomics, which has promoted the upgrading of the company's synthetic biotechnology in veterinary vaccines, antibody drugs, enzyme preparations, probiotics, and related intermediates. The company has continued to establish research institutes and colleges such as the Tianjin Institute of Industrial Biotechnology of the Chinese Academy of Sciences and Shanghai Jiaotong University
Reipu Biotech (300119.SZ): In the future, it is planned to launch products such as oral insect repellents, cat fever monoclonal antibodies, canine quadruplets, etc.
Gelonghui, April 26, 丨 Ruipu Biotech (300119.SZ) held a performance briefing on April 25, 2024, to discuss “What is the current channel development situation in the pet sector and the channel side plans for this year? What big products are worth looking forward to?” The company replied that the company has set up nearly 100 core dealers in all provinces and cities across the country, covering major Tier 1 and 2 cities across the country, and has covered more than 5,000 channel stores nationwide. In 2024, the company will continue to optimize dealers and sink channels to prefecture-level markets; form a mutually beneficial and win-win mechanism with core dealers, deepen cooperation and bonds; and strengthen
Ruipu Biotech (300119.SZ): This year, the company also plans to market a live recombinant H5 vaccine against duck fever, as well as several Chinese veterinary drugs such as bacteriophages and Xubiying extract
Gelonghui, April 26, 丨 Ruipu Biotech (300119.SZ) held a performance briefing on April 25, 2024 to discuss “What major products will the company launch in the poultry sector in the past two years?” The company replied that in the poultry sector, the company focuses on multivalent multivalent vaccines, original pharmaceutical preparations, Chinese veterinary medicine products, etc. Recently, the company received three new veterinary drug certificates for the triple inactivated vaccine (LaSota strain+TJ-4 strain+RP-8-c strain), and Avian Adenovirus (H9 subtype), and aims to launch it on the market this year. In addition, the company also plans to go public and restructure Duck Fever this year
No Data